Observational study on CNS inflammatory demyelinating diseases in the Chinese population
Sun Yat-Sen Prospective Cohort Study of Central Nervous System Idiopathic Inflammatory Demyelinating Diseases
This study is looking to understand how certain brain diseases, like Multiple Sclerosis, affect people in China and what factors might influence their progression and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 450 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06541626 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the pathogenesis and clinical prognosis of central nervous system idiopathic inflammatory demyelinating diseases (CNS IIDD) such as Multiple Sclerosis and Neuromyelitis Optica in the Chinese population. It will clarify clinical characteristics and prognostic factors of these diseases while analyzing the relationship between biomarkers and disease progression. Participants will receive standard diagnosis and treatment plans based on current guidelines, along with clinical evaluations and follow-ups from neuroimmunology specialists.
Who should consider this trial
Good fit: Ideal candidates are patients aged 18-65 years diagnosed with CNS idiopathic inflammatory demyelinating diseases.
Not a fit: Patients with a history of central nervous system tumors or other specified demyelinating diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of CNS IIDD and improve clinical treatment decisions for patients.
How similar studies have performed: Other studies have shown success in understanding CNS IIDD through observational approaches, making this study a continuation of established research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients aged 18-65 years with central nervous system idiopathic inflammatory demyelinating diseases (CNS IIDD); 2. The clinical syndrome of the attack meets one of the following: MS, NMOSD, MOGAD, ADEM, clinically isolated syndrome, demyelinating encephalopathy, demyelinating myelitis, or brainstem encephalitis (see below A-E); 3. Agree to participate in this study and sign the informed consent form. Exclusion Criteria: 1. History of tumors or diagnosis of central nervous system tumors; 2. Infectious lesions of the central nervous system; 3. Hereditary, metabolic, toxic, vascular, or traumatic demyelinating diseases of the brain/spinal cord; 4. Non-compliance with treatment and follow-up.
Where this trial is running
Guangzhou, Guangdong
- Sun Yat-sen Memorial Hospital — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Hongxuan Wang
- Email: wanghx8@mail.sysu.edu.cn
- Phone: 86+13824498978
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.